Theranos
Theranos Blood Testing Patient Safety Failures
Estimated impact: $9B valuation destroyed; patient safety compromised
Theranos deployed its unreliable Edison blood testing devices in Walgreens stores, delivering inaccurate results to real patients. Patients received false positives and negatives for conditions including cancer and HIV, leading to unnecessary treatments, emotional distress, and delayed diagnoses for serious conditions.
Decision context
Whether to deploy blood testing devices in retail pharmacies for patient use before the technology had been validated through proper clinical trials and regulatory review.
Biases present in the decision
Toxic combinations
- Yes Committee
- Echo Chamber
- Golden Child
Reference class base rates
Across all 146 curated case studies in our library:
Lessons learned
- Authority bias led Walgreens to trust Theranos's claims and deploy unvalidated medical devices in their pharmacies.
- Confirmation bias caused Theranos to cherry-pick quality control results and dismiss failed test runs.
- Patient safety must never be subordinated to commercial launch timelines, regardless of investor pressure.
Source: FDA Warning Letter to Theranos Inc. (2015); CMS Inspection Report (2016); John Carreyrou, "Bad Blood" (2018) (FDA Action)
See what we'd flag in your next strategic memo.
Upload a strategic memo or board deck. Get the same bias audit you just saw for Theranos, on your own high-stakes call, in under 60 seconds.
Or leave your email, we'll run a strategic memo of your choosing and send the readout within a business day.
Ready to audit your own memo right now? Create a free account →